Trends in NIH Funding of Dermatology Research, 2015-2019
Distribution patterns in research funding reflect a wide gender gap and suggest the need for continued support of women in research.
General Dermatology
Could Erythema Multiforme and Urticaria Confer a Better Outcome of COVID-19?
Data may support the theory that patients with erythema multiforme or urticaria are less affected by coronavirus disease 2019 (COVID-19).
Lifestyle, Age, and Sex Affect Several Biophysical Properties of the Skin
Sleep, diet, digital use, age, and sex all influence sebum content, stratum corneum hydration, and pH of skin.
Missed Diagnosis of Lipohypertrophy by Inspection and Palpation: Prevalence and Contributing Risk Factors
There is a high false-negative rate for lipohypertrophy diagnosis on physical examination in patients with type 1 or type 2 diabetes.
Lack of Efficacy, Safety Data for Dietary Supplements Frequently Used in Dermatology
Although some evidence suggests certain supplements are beneficial in addressing dermatologic issues, the use of other supplements lacks clinical support.
Depression Raises Risk for Developing Autoimmune Skin Disease
Insufficiency of T-regulatory cells, which maintain immune system equilibrium and inhibit proinflammatory cell responses, may be a factor in the pathogenesis of MDD.
Q&A: Study of Lenabasum in dcSSc Shows Immunosuppressive Therapy Variability by Geographic Region
In a study of lenabasum treatment in systemic sclerosis, researchers evaluated variability of immunosuppressive therapy by geographic region; includes Q&A with study lead author, Dr Christopher Denton.
Is It COVID-19 or Is It Your Meds?
Taste and smell disturbances are common symptoms of COVID-19, but they can also be caused by medications frequently prescribed by dermatologists.
Recommendations for Managing Cutaneous Lymphoma During COVID-19
A new guideline provides strategies for managing patients with primary cutaneous lymphoma during the COVID-19 pandemic.
FDA Grants Orphan Drug Status to Antifibrotic Therapy for Systemic Sclerosis
TLY012, a PEGylated recombinant human TRAIL (TNF-related apoptosis-inducing ligand) protein, binds upregulated death receptor 5 (DR5) on myofibroblasts (MFBs) and selectively blocks activation of MFBs in fibrotic regions.
-
Loading...
-
Loading...
Next post in General Dermatology
